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Text plus references [1506]  
Heart failure (HF), which is the end stage of most cardiovascular diseases (CVDs),[1] is a 
global public health burden which is associated with substantial morbidity, mortality as well 
as health care costs.[2] In the USA alone, HF contributes to about $31 billion in annual 
healthcare expenditure.[3] With recent advances in treatment of CVDs which have led to 
their decline, there has been an increase in the prevalence of HF over the last few 
decades.[4] The increasing prevalence of HF has been reported to reflect a combination of 
factors such as aging of the population and improvements in the treatment of CVDs.[4] In the 
USA, HF affects approximately 6.5 million Americans[5] and it has been projected that 8 
million people will be affected by 2030.[5] Heart failure has considerable impact on both the 
economy and society, hence HF prevention strategies should be urgently considered. 
 
According to a report from the American Heart Association (AHA), optimal profiles in 
smoking, body mass index, physical activity, diet, blood pressure, glucose as well as 
cholesterol are associated with a lower lifetime risk of HF.[5] The 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors (statins), are established for the primary and secondary 
prevention of CVD and this is based on their lipid-lowering properties.[6-8] Statins promote 
lipid-lowering by inhibiting cholesterol biosynthesis and enhancing low-density lipoprotein 
(LDL) clearance from the circulation. Beyond their lipid-lowering properties, statins are also 
suggested to have several pleiotropic effects and these include decreasing oxidative stress 
and inflammation, improving endothelial function, enhancing stability of atherosclerotic 
plaques, decreasing platelet activation, inhibiting thrombosis, and inhibition of smooth 
muscle proliferation.[9, 10] Statins have been reported to lower HF risk by reducing the risk 
and progression of coronary heart disease (via their cholesterol lowering effects);[11, 12] 
they also have a beneficial effect on clinical outcomes in HF patients,[13] which may be via 
some of their pleiotropic effects. Statins are classified into hydrophilic and lipophilic groups 
based on tissue selectivity. Lipophilic statins are widely distributed in different tissues, 
whereas hydrophilic statins are liver-specific.[14] Lipophilic statins include atorvastatin, 
simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin; while hydrophilic statins 
include rosuvastatin and pravastatin. Hydrophilic statins employ carrier-mediated 
mechanisms for uptake, which could reduce their ability to exert non-lipid effects on extra 
hepatic tissues[14] and they are suggested to be less pleiotropic. Though a head-to-head 
comparison is not yet available, pooled data based on an indirect comparison approach 
suggests that lipophilic statins have more beneficial effects on HF-related clinical outcomes 
compared to hydrophilic statins (rosuvastatin).[15]  
 
Based on the limited data regarding the clinical impact of different statins on future HF risk 
according to lipophilicity, Imran and colleagues present novel data comparing the risk of 
incident HF between hydrophilic and lipophilic statins.[16] Using a large observational cohort 
based on claims data of approximately 8 million patients with a mean age of 58 years, the 
risk of incident HF between initiators of hydrophilic statins and those of lipophilic statins was 
compared after propensity matching. Effect estimates for HF were also estimated separately 
for low- and high-intensity users. After a median follow-up of 2 years, 8,389 incident HF 
cases were recorded. The results suggested a modest reduction in HF for hydrophilic statins 
compared with lipophilic statins, which seemed to be driven by high-dose rather than low-
dose hydrophilic statins. There was no evidence of effect modification on the association by 
sex, gender, and specific statins (rosuvastatin versus atorvastatin). Furthermore, the results 
appeared to be robust in a number of sensitivity analyses. The authors postulated several 
reasons for the difference in HF risk between hydrophilic and lipophilic statins and these 
included differing pleiotropic effects and solubilities, cytokine action, and glucose 
homeostasis. Given that these reasons were mainly speculative, the authors acknowledged 
the association between statin lipophilicity and HF risk to be a complex one and called for 





The strengths of the current study include the novelty, the large sample size with use of real 
world data and its generalizability to the United States population, use of a comprehensive 
panel of covariates with utilization of propensity score matching, incorporation of a lag of one 
year to reduce the potential misclassification of previously subclinical HF, and several 
sensitivity analyses to ensure robustness of results. Despite the adjustment for several 
covariates and using propensity matching, there was still a potential for residual confounding 
given the observational design. Another limitation was the inability to adjudicate HF events. 
In light of the limited data available, the authors called for more research in other 
populations.  
 
Despite the modest risk reduction associated with use of hydrophilic compared with lipophilic 
statins, the current findings are very timely and relevant.[16] Though statins have been 
reported to reduce the future risk of HF, it appears this effect may be driven by high-dose 
hydrophilic statins such as rosuvastatin. The clinical question is should statins be prescribed 
to reduce the risk of HF based on lipophilicity? It may be too early to say so as the current 
evidence is based on a single observational cohort. Whether hydrophilic statins would be 
beneficial for HF prevention need to be resolved in future studies. More importantly, 
definitive interventional evidence is needed to corroborate these early findings. 
Nevertheless, we commend the authors for putting together this fine study on the 
comparative effects of hydrophilic and lipophilic statins on future HF risk. Indeed, as the 
authors have clearly acknowledged in their conclusions, further work is needed. This 
investigation should stimulate further studies in the topic area. The potential relevance of 
statin lipophilicity in HF prevention may have some clinical implications, but the AHA reports 
that the primary prevention of HF can be augmented by greater adherence to its “My Life 
Check - Life’s Simple 7 goals”, which involve improving 7 major risk factors (smoking, body 
mass index, physical activity, diet, blood pressure, glucose, and cholesterol) through lifestyle 
changes and this remains the cornerstone of HF prevention. 
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